Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

Marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway inhibitor, demonstrated safety and efficacy in preventing bleeding episodes in patients with haemophilia. This multicentre, open‐label study investigated safety, tolerability, and efficacy of long‐term weekly p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny, Luis Lamas, Jose, Cristobal Morales, Juan, Malan, Daniel R., Teeter, John, Charnigo, Robert J., Hwang, Eunhee, Arkin, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Platelets, Thrombosis and Haemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092220/
https://www.ncbi.nlm.nih.gov/pubmed/36220152
http://dx.doi.org/10.1111/bjh.18495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092220/
https://www.ncbi.nlm.nih.gov/pubmed/36220152
http://dx.doi.org/10.1111/bjh.18495

Ejemplares similares